In addition to its CNS focus, Jupiter is evaluating opportunities in longevity and metabolic health. Emerging data suggests that JOTROL’s inhibition of NLRP3, when combined with GLP-1 treatments, ...

Jupiter Neurosciences (JUNS) announced a strategic focus on targeting the NLRP3 inflammasome in all upcoming clinical trials. This shift aims ...

With its ability to safely reach therapeutic levels in plasma and cross the blood-brain barrier, JOTROL represents a groundbreaking advance for targeting neuroinflammatory pathways like NLRP3.

【导读】脑内出血（ICH）是严重类型的脑卒中，具有高死亡率和有限的选择治疗。12月23日，郑大一附院与中国科学院以及台北医学大学研究人员合作共同在期刊《Cell Death&Disease》上发表了研究论文，题为“Sphk1/S1P pathway ...

With its ability to safely reach therapeutic levels in plasma and cross the blood-brain barrier, JOTROL represents a groundbreaking advance for targeting neuroinflammatory pathways like NLRP3. "By ...

NLRP3 inflammasome activation, pro-inflammatory cytokine production and pyroptosis are key features of inflammation that contribute to liver fibrosis progression, cirrhosis and end-stage liver failure ...

Nanjing Mingde New Drug Research Co. Ltd. has identified NLRP3 inflammasome inhibitors reported to be useful for the treatment of inflammation.

AZM-152 works by blocking the NLRP3 inflammasome, a crucial inflammatory pathway involved in BPD and other diseases. This compound specifically targets the receptor for hyaluronan-mediated ...